Explore the Day 1 subscription performance of Goldline Pharmaceutical Ltd. IPO, including investor participation, price band details, issue size, key dates, and the process to apply through ASBA or UPI.
The Goldline Pharmaceutical Ltd. IPO opened for subscription on May 12, 2026, marking the company’s public market debut in the SME segment. The company operates in the pharmaceutical sector and plans to utilise the issue proceeds primarily for repayment of borrowings and general corporate purposes.
The IPO is a book-built fresh issue aggregating to ₹11.61 Crores. The issue is priced between ₹41 and ₹43 per share with a face value of ₹10 per share.
The Goldline Pharmaceutical Ltd. IPO witnessed strong investor demand on the first day of subscription, led by retail investor participation.
On the opening day, the Goldline Pharmaceutical Ltd. IPO was subscribed 15.75× overall.
| Investor Category | Subscription (Times) |
|---|---|
Qualified Institutional Buyers (QIBs) |
1.31× |
Retail Individual Investors (RIIs) |
26.55× |
Non-Institutional Investors (NIIs) |
12.10× |
Total |
15.75× |
The retail category emerged as the strongest contributor on Day 1, while institutional and non-institutional investors also recorded healthy participation levels.
On the second day of bidding, the Goldline Pharmaceutical Ltd. IPO witnessed exceptionally strong investor demand across all categories. The IPO was subscribed 68.14× overall, reflecting significant market interest.
| Investor Category | Subscription (Times) |
|---|---|
Qualified Institutional Buyers (QIB) |
1.31× |
Retail Individual Investors (RII) |
105.95× |
Non-Institutional Investors (NII) |
72.05× |
Total |
68.14× |
The retail investor category emerged as the strongest contributor on Day 2, crossing 100× subscription, while non-institutional investors also recorded substantial demand. The strong response indicates broad-based participation across investor segments.
On the final day of bidding, the Goldline Pharmaceutical Ltd. IPO witnessed exceptionally strong demand across all investor categories. The IPO closed with an overall subscription of 557.47×, indicating substantial investor interest in the issue.
| Investor Category | Subscription (Times) |
|---|---|
Qualified Institutional Buyers (QIB) |
106.39× |
Retail Individual Investors (RII) |
645.39× |
Non-Institutional Investors (NII) |
868.91× |
Total |
557.47× |
The non-institutional investor category emerged as the strongest contributor with subscription exceeding 868×, while retail investors also recorded extremely high demand. The final subscription figures reflect broad-based participation and significant interest across all investor segments.
The IPO price band is fixed between ₹41 and ₹43 per share. Investors can apply for a minimum of 1 lot comprising 3,000 shares.
At the upper end of the price band, the minimum investment amount stands at ₹1,29,000. Applications under the SME IPO framework are accepted in fixed lot sizes in accordance with exchange guidelines.
| Investor Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
Retail (Minimum) |
1 |
3,000 |
₹1,29,000 |
S-HNI (Minimum) |
2 |
6,000 |
₹2,58,000 |
The IPO follows the SME application structure with fixed lot-based bidding.
For detailed insights about the company, issue particulars, and the latest updates, visit the Goldline Pharmaceutical IPO on Bajaj Markets.
The IPO timeline is provided below:
| Event | Date | Details |
|---|---|---|
IPO Open Date |
May 12, 2026 |
Issue opens for subscription |
IPO Close Date |
May 14, 2026 |
Final day for bidding |
Basis of Allotment |
May 15, 2026 |
Allotment finalisation |
Initiation of Refunds |
May 18, 2026 |
Refunds begin |
Credit of Shares to Demat |
May 18, 2026 |
Shares credited |
Listing Date |
May 19, 2026 |
Proposed listing on BSE SME |
Note: These dates represent procedural milestones based on publicly available data and are intended for informational purposes only.
Investors may apply through ASBA-enabled bank accounts or UPI-supported broker platforms for this IPO.
This is a convenient and secure method where your application amount stays blocked until shares are allotted.
Log in to your internet banking account.
Go to the ‘Investments’ or ‘IPO Application’ section.
Select ‘Goldline Pharmaceutical Ltd. IPO’ from the available list.
Enter your preferred bid quantity and price.
Confirm and submit your application.
The bid amount will remain blocked in your account until allotment.
Upon allotment, the amount will be debited, and shares credited to your Demat account.
You can apply using UPI through your stockbroker’s or financial marketplace’s online platform.
Log in to your trading account or Demat account on your broker’s platform or financial marketplace.
Navigate to the IPO section and select ‘Goldline Pharmaceutical Ltd. IPO’.
Enter your application details including number of lots and price.
Provide your UPI ID linked to your bank account.
Approve the UPI mandate request on your UPI app (like BHIM, Google Pay, or PhonePe).
Funds will be debited only upon share allotment.
Once allotted, shares will be credited directly to your Demat account.
The information provided above is based on publicly available data from reliable financial news and market sources. Investors are advised to verify figures and consult financial experts before making investment decisions. Market conditions and subscription numbers are subject to change during the IPO window.
Sources
LiveMint — IPO News and Updates, https://www.livemint.com/market/ipo
Economic Times — IPO News: Latest IPO News, Upcoming IPO, https://economictimes.indiatimes.com/markets/ipo
Financial Express — IPO News, https://www.financialexpress.com/market/ipo-news/
NDTV Profit — IPOs, https://www.ndtvprofit.com/ipos
Business Today — IPO Corner: Latest IPO News & Analysis, https://www.businesstoday.in/markets/ipo-corner